Lundbeck
33.8 DKK -0.71%2 investors are following this company
Lundbeck is a pharmaceutical company. The greatest focus is found in research on psychiatric and neurotic disorders, which includes the treatment of depression, schizophrenia, Alzheimer's and Parkinson's syndrome. The company conducts research, development and distribution of medicines where the customer base can be found on a global level. The company was originally founded in 1915 and has its headquarters in Valby.
Revenue
19.91B
EBIT %
16.05 %
P/E
14.63
Dividend yield-%
2.07 %
Target price
-
Recommendation
-
Updated
-
NASDAQ Copenhagen
HLUN B
Daily low / high price
33.64 / 34.12
DKK
Market cap
33.66B DKK
Turnover
2.79M DKK
Volume
82K
Financial calendar
Interim report
15.05.2024
Interim report
21.08.2024
Interim report
13.11.2024
ShowingAll content types
H. Lundbeck A/S: Abilify Maintena[®] 960 mg (aripiprazole) approved in the EU as the first once-every-two-months long-acting injectable for the maintenance treatment of schizophrenia
H. Lundbeck A/S: Lundbeck held its Annual General Meeting on 20 March 2024 at the company's registered office
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools